Results 1 to 10 of about 48,562 (198)
Itch and Janus Kinase Inhibitors
Acta Dermato-Venereologica, 2023 Itch is a common skin symptom, with complex aetiology and pathogenesis. It is mediated by 2 pathways, the histaminergic and non-histaminergic pathways.
Yujin Han +4 more
doaj +5 more sources
Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
Molecules, 2023 Janus kinase inhibitors, also known as JAK inhibitors, JAKinibs or JAKi, are a new group of disease-modifying drugs. They work by inhibiting enzymes involved in the transmission of information from receptors located in the cell membrane to the cell ...
Izabella Ryguła +2 more
doaj +4 more sources
Role of Janus Kinase Inhibitors in Therapy of Psoriasis [PDF]
Journal of Clinical Medicine, 2021 Janus kinases inhibitors are molecules that target Janus kinases—signal transducers and activators of transcription (JAK/STAT). They inhibit this intracellular signal pathway, blocking the gene transcription of crucial proinflammatory cytokines that play a central role in the pathogenesis of many inflammatory and autoimmune diseases, including ...
Sylwia Słuczanowska-Głąbowska +3 more
openaire +3 more sources
Janus Kinase Inhibitors and Cell Therapy [PDF]
Frontiers in Immunology, 2021 Cellular therapies such as allogeneic hematopoietic stem cell transplantation (HSCT) and immune-effector cell therapy (IECT) continue to have a critical role in the treatment of patients with high risk malignancies and hematologic conditions.
Amer Assal +2 more
doaj +3 more sources
Immunological Medicine, 2023 Recent studies have gradually elucidated the pathogenesis of inflammatory bowel disease; thus, the Janus kinase (JAK)-signal transducers and activators of transcription pathway are strongly involved in the pathophysiology of inflammatory bowel disease ...
Hiroshi Nakase
doaj +2 more sources
Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis
The Cochrane Library, 2015 Myelofibrosis is a bone marrow disorder characterized by excessive production of reticulin and collagen fiber deposition caused by hematological and non-hematological disorders. The prognosis of myelofibrosis is poor and treatment is mainly palliative.
Arturo J Martí-Carvajal +2 more
exaly +5 more sources
Janus kinase inhibitors in autoimmune bullous diseases
Frontiers in Immunology, 2023 Autoimmune bullous disease (AIBD) is a severe skin disorder caused by autoantibodies that target intercellular or cell-matrix adhesion proteins.
Dawei Huang +9 more
doaj +3 more sources
Janus kinase inhibitors in immunoinflammatory rheumatic diseases
Терапевтический архив, 2022 Despite great advances in the diagnosis and treatment of immunoinflammatory rheumatic diseases, which have led to a significant improvement in the prognosis in many patients, the fundamental medical problems of this pathology the restoration of the ...
Evgeny L. Nasonov
doaj +3 more sources
Janus Kinase inhibitors in the treatment of large vessel vasculitis: a systematic review and meta-analysis [PDF]
Open MedicineThis meta-analysis evaluates Janus Kinase (JAK) inhibitors’ efficacy and safety in large vessel vasculitis (LVV), encompassing Giant Cell Arteritis (GCA) and Takayasu’s Arteritis (TAK).
Bai Yang, Wang Zhe, Zhang Chunling
doaj +2 more sources
Janus kinase inhibitors - their current applications and future prospects [PDF]
Farmacja Polska, 2022 Janus kinase inhibitors are a group of drugs that provide an alternative to conventional therapy for numerous diseases. The most studied drug of this group is tofacitinib.
Natalia Wierzbowska +4 more
doaj +1 more source